Please assess the completion status of the following clinical trial:

Trial Title: Open Label Extension Study of Romiplostim (AMG 531) in Thrombocytopenic Patients With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Must have previously completed a romiplostim ITP study~* Platelet count ≤ 50 x 10 \^9/L~* Written informed consent~Exclusion Criteria:~* Bone marrow stem cell disorder or new active malignancies diagnosed since enrollment in the previous romiplostim ITP study~* Received any alkylating agents within 4 weeks before screening visit or anticipated use during the time of the proposed study~* Currently enrolled in or has not yet completed at least 4 weeks since ending device or drug trial(s) (other than the previous romiplostim ITP study), or subject is receiving other investigational agent(s) other than romiplostim~* Not using adequate contraceptive precautions~* Not available for follow-up assessments~* Has any kind of disorder that compromises the ability of the participant to give informed consent and does not have a legally-acceptable representative and/or is unable to comply with study procedures.

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Romiplostim (Type: EXPERIMENTAL): Romiplostim weekly subcutaneous dosing based on screening weight and platelet count. Starting dose of 1 µg/kg up to a maximum dose of 10 µg/kg.

Based on this trial design, predict the completion outcome and termination type (if applicable).